Skip to content

Janux Therapeutics JANX Book value per share

Book value per share at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$33.20+3.0%
Amgen logo
AmgenAMGN
$16.89+47.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$291.77+10.4%
Xencor logo
XencorXNCR
$6.85-21.1%
AbbVie logo
AbbVieABBV
-$3.75-568%
Vor Biopharma logo
Vor BiopharmaVOR
-$3.50-133%

Other financials

Income statement

See full
Revenue$3.7M
Operating income-$34.2M+2.0%
Net income-$24.4M-3.6%
EPS (diluted)-$0.39-2.6%

Balance sheet

See full
Cash & equivalents$51.8M-29.7%
Total debt$21.6M-4.6%
Total equity$941.5M-7.0%
Total assets$1.0B-2.1%

Cash flow

See full
Operating cash flow-$12.3M+27.5%
CapEx$273.0K-26.4%
Free cash flow-$12.6M+27.5%

Valuation

See full
Market cap$889.15M-36.3%
Enterprise value$858.89M-36.2%
P/S64.8×-84.8×

Profitability

See full
Operating margin-1,143.1%-65.1pp
Net margin-833.6%+0.9pp
FCF margin-571.6%+98.3pp

Returns & leverage

See full
Return on equity-11.7%+4.1pp
Debt / equity0.0×
Current ratio17×-41.5×

Where this comes from

Calculated from Janux Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Janux Therapeutics's book value per share?
Janux Therapeutics (JANX) reported book value per share of $15.02 in Q1 2026.
How has Janux Therapeutics's book value per share changed year-over-year?
Janux Therapeutics's book value per share decreased by 8.3% year-over-year, from $16.39 to $15.02.
What is the long-term trend for Janux Therapeutics's book value per share?
Over 5 years (2020 to 2025), Janux Therapeutics's book value per share has grown at a -0.7% compound annual growth rate (CAGR), from -$16.00 to $15.44.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.